Compared with placebo , a greater proportion of patients treated with ATX-101 1 and 2 mg/cm ( 2 ) showed a 1-point improvement in CR-SMFRS ( 58.3 % and 62.3 % , respectively , vs. 34.5 % with placebo ; P < 0.001 ) and patient satisfaction ( SSRS score 4 ) with the appearance of their face and chin ( 68.3 % and 64.8 % , respectively , vs. 29.3 % ; P < 0.001 ) .